Details for Patent: 8,435,945

Title:	GH secretagogues and uses thereof
Abstract:	The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
Inventor(s):	Abribat; Thierry (St-Foy-les-Lyons, FR), De Villers; Andre (Outremont, CA), Chapdelaine; Alcide (Ile des Soeurs, CA), Allas; Soraya (Iles des Soeurs, CA), Gravel; Denis (Saint-Lambert, CA)
Assignee:	Theratechnologies Inc. (Montreal, CA)
Filing Date:	Sep 26, 2008
Application Number:	12/239,708
Claims:	1. A method of treating HIV-related lipodystrophy in a subject in need thereof, without a significant impairment of glucose control and with a decrease in (a) total cholesterol, (b) non-HDL cholesterol, or (c), both (a) and (b), said method comprising administering to said subject (i) (hexenoyl trans-3)hGRF(1-44)NH.sub.2, or (ii) a composition comprising said (hexenoyl trans-3)hGRF(1-44)NH.sub.2and a pharmaceutically acceptable carrier. 2. The method of claim 1, wherein said subject is receiving antiviral therapy. 3. The method of claim 1, wherein said subject also suffers from diabetes, glucose intolerance or insulin resistance. 4. The method of claim 1, wherein said (hexenoyl trans-3)hGRF(1-44) NH.sub.2 is administered at a dose of about 1 mg or about 2 mg. 5. The method of claim 1, wherein said (hexenoyl trans-3)hGRF(1-44) NH.sub.2 or said composition is administered by an intravenous, oral, transdermal, subcutaneous, mucosal, intramuscular, intranasal, intrapulmonary, parenteral, intrarectal or topical route. 6. The method of claim 5, wherein said (hexenoyl trans-3)hGRF(1-44) NH.sub.2 or said composition is administered by a subcutaneous route. 7. The method of claim 4, wherein said (hexenoyl trans-3)hGRF(1-44) NH.sub.2 is administered at a dose of about 2 mg. 8. The method of claim 1, wherein said method is with a decrease in total cholesterol. 9. The method of claim 1, wherein said method is with a decrease in non-HDL cholesterol. 10. The method of claim 1, wherein said method is with a decrease in both total cholesterol and non-HDL cholesterol.